X-Chem Pharmaceuticals and Vertex Pharmaceuticals will jointly develop small molecules targeting cystic fibrosis (CF) and other severe genetic diseases. Under the…
Articles by Daniela Semedo, PhD
Dalton and Arch Biopartners are partnering to manufacture AB569 for clinical trials involving cystic fibrosis (CF) patients with chronic,…
Savara has received U.S. and Canadian patents for its AeroVanc powdered, inhaled formulation of the antibiotic vancomycin hydrochloride, which combats treatment-resistant…
Fifteen non-profit groups in seven countries will receive Cystic Fibrosis Circle of Care project grants totaling nearly $1 million this year,…
A new test able to screen for the risk for inherited conditions such as cystic fibrosis (CF) will be jointly commercialized by…
The United States and Canada have given Laurent Pharmaceuticals a green light for a Phase 2 clinical trial of LAU-7b as…
Arch Biopartners is on the verge of its first clinical trial of AB569, an inhalation treatment for antibiotic-resistant bacteria…
Enterprise Therapeutics has received a £95,000 grant from Britain’s Cystic Fibrosis Trust to develop innovative treatments for cystic fibrosis (CF). The…
AbbVie is accepting applications for its 2017 AbbVie CF Scholarship program that helps to support outstanding young adults with…
Corbus Pharmaceuticals recently reported that its Phase 2 clinical trial examining multiple doses of anabasum (formerly known as JBT-101 or Resunab)…